Please login to the form below

Not currently logged in
Email:
Password:

Ongentys

This page shows the latest Ongentys news and features for those working in and with pharma, biotech and healthcare.

Neurocrine bags FDA approval for first tardive dyskinesia drug

Neurocrine bags FDA approval for first tardive dyskinesia drug

The COMT inhibitor was approved in Europe as Ongentys last June as an adjunct to Parkinson's disease treatment, and Neurocrine is hoping to meet with the FDA to see what

Latest news

  • EC approves Bial’s Parkinson’s disease therapy EC approves Bial’s Parkinson’s disease therapy

    Manufactured by Bial, Ongentys (opicapone) is indicated as adjunctive therapy to preparations of levodopa/DOPA decarboxylase inhibitors (DDCIs) in adults with Parkinson's and end-of-dose motor fluctuations who cannot ... Bial says its drug will be

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2017 Deal Watch February 2017

    Royalty monetisation. 150. BIAL/ Neurocrine Biosciences. ONGENTYS (opicapone), COMT inhibitor for Parkinson's disease (approved in EU).

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Frontera Group

Welcome to Frontera Group where our agencies immerse you in the world of the patient...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics